Swiss pharmaceutical giant Novartis announced Monday, October 25 that a treatment under study has failed to meet its primary goals in a phase III study for a form of lung cancer. This treatment, called canakinumab, used in these trials in combination with the anti-cancer drug pembrolizumab and chemotherapy, did not demonstrate statistically significant differences in terms of survival or progression-free survival in patients with of the disease having received these two treatments, plus a placebo, he said in a press release.
These phase III trials called Canopy-1 studied this treatment in patients with locally advanced or metastatic so-called “non-small cell” lung cancer who had not yet received previous treatments. The data from these trials, however, showed potentially clinically significant improvements in certain pre-specified patient subgroups, both in terms of survival and disease progression-free survival, added the Swiss group which will continue to analyze. the data.
>> To read also – Sanofi, Novartis … here are the best employers of the
health and pharmacy
Lung cancer is one of the most common forms of cancer worldwide with two million new cases diagnosed each year, Novartis said. There are two main types of lung cancer with one side those with small cells and the other those called “non-small cells” which represent about 85% of diagnosed lung cancers.
>> Read also – Novartis launches trials for an anti-Covid-19 treatment, encouraging results
–
Receive our latest news
Every morning, the information to remember about financial markets.
